NasdaqGM:APGEBiotechs
A Look At Apogee Therapeutics (APGE) Valuation After Wider Losses And A New Shelf Registration
Why Apogee Therapeutics is in focus after earnings and a new shelf registration
Apogee Therapeutics (APGE) has come into focus after reporting a full year 2025 net loss of US$255.84 million, along with a new US$287.29 million shelf registration for additional common stock.
See our latest analysis for Apogee Therapeutics.
At a share price of US$73.05, Apogee Therapeutics has delivered a 30 day share price return of 17.37% and a 1 year total shareholder return of 94.59%. This suggests that...